Erratum: Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E-coli preparation (DSM17252) compared to placebo (Zeitschrift fur Gastroenterologie (2009) 47:2 (209-214) DOI: 10.1055/s-2008-1027702);Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo

Zeitschrift fur Gastroenterologie

Volumn 47, Issue 2, 2009, Pages 209-214

  Enck, P ^a   Zimmermann, K ^b   Menke, G ^c   Klosterhalfen, S ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Symbio Herborn Group GmbH   (Germany)

^c PAZ Arzneimittel Entwicklungsgesellschaft MbH   (Germany)

Author keywords

Gastroenterology; Irritable bowel syndrome; Primary care; Probiotics

Indexed keywords

PROBIOTIC AGENT; SYMBIOFLOR 2; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ESCHERICHIA COLI; FATIGUE; FEMALE; GENERAL PRACTITIONER; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PHYSICIAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 62349128091     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0034-1366796     Document Type: Erratum

References (43)

1. Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. J Clin Gastroenterol 2005; 39: S243-S246
2. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
3. Nobaek S, Johansson ML, Molin C et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238
4. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294-301
5. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147
6. Sen S, Mullan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299 V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620
7. Niv E, Naftali T, Hallak R et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a doubleblind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931
8. Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590
9. Guyonnet D, Chassany P, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486
10. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2006; 17:687-696
11. Saggioro A. Probiotics in The treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38: 104-106
12. Tsuchiya J, Barreto R, Okura R et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-174
13. Kajander K, Hatakka K, Poussa T et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-394
14. Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. Scand J Prim Health Care 1989; 7: 23-26
15. Bruckschen E, Horosiewicz H. Chronische Obstipation. Vergleich von mikrobiologischer Therapie und Lactulose. Münch Med Wochenschr 1994; 136: 241-245
16. Krammer HJ, Kämper H, v Bünau R et al. Probiotische Arzneimittelthe-rapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 2006; 44: 651 -656
17. Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Ergebnisse einer klinischen Studie zur Wirksamkeit und Verträglichkeit der mikrobiologischen Therapie mit dem E.-coli-Stamm Nissle 1917 (Mutaflor®). Medizinische Klinik 1994; 89: 587-593
18. Enck P, Zimmermann K, Menke G et al. A mixture of E. coli (DSM17252) and Enterococcus faecalis (DSM16440) for treatment of the irritable bowel syndrome - a randomized controlled trial with primary care physicians. Neurogastroenterol Motil: (in press)
19. Smith GD, Steinke DT, Kinnear M et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the episode IBS study. Brit J Clin Pract 2004; 54: 503-507
20. Van der Horst HE, van Dülmen AM, Schellevis EG et al. Do patients with irritable bowel syndrome in primary care really diifer from outpatients with irritable bowel syndrome? Gut 1997; 41: 9969-9974
21. Bijkerk CJ, de Wit NJ, Stalman WA et al. Irritable bowel syndrome in primary care: the patients' and doctors' view on symptoms, etiology and management. Can J Gastroenterol 2003; 17: 363-368
22. Thompson WG, Heaton KW, Irvine EJ et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): 43-47
23. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
24. rd editition
25. Thompson WG. The road to Rome. Gastroenterology 2006; 130: 1552-1556
26. nd edition
27. Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel syndrome. Brit Med J 1978; 2: 653-654
28. Thompson WG. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenteroly Int 1989; 2: 92-95
29. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Zelnorm (Tegaserod Maleate) Tablets; Application No: 21-200. Approval Date: 7/24/2002. http://www.fda.gov/cder/ foi/nda / 2002/21-200-Zelnorm.htm
30. EMEA, Committee for Proprietary Medicinal Products. Points to consider on evaluation of medicinal products for the treatment of irritable bowel syndrome. Document: CMPM/EMW/785/97, published: 19.3.2003
31. Panijel M, Burkard I. Pro-Symbioflor for treatment of the irritable colon. Jatros Naturheilkunde 1993; 2 (3): 1-4
32. Wirksamkeit und Verträglichkeit von Symbioflor®-2 Randomisierte, multizentrische, doppelblinde, Placebo-kontrollierte Prüfung an 298 Patienten mit Reizdarmsyndrom unter 8-wöchiger Dauerbehandlung mit Symbioflor® 2 (Klinische Phase IV). Ergänzender Integrierter Klinischer Studien-Bericht, Endgültig PAZ 9527-5-S2 Frankfurt, 4.7.2005
33. Rusch V, Hyde RM, Ludley TD. Documentation of identiy, production, harmlessness, efficacy, and durability of Symbioflor preparations. Mikroökologie und Therapie 1980; 10: 173-203
34. Kruis W, Thieme C, Weinzierl M et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7
35. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17: 325-331
36. Gordon S, Ameen V, Bagby B et al. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003; 48: 1317-1323
37. Irvine AJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-1551
38. Dehlink E, Domig KJ, Loibichler C et al. Heat- and formalin-inactivated probiotic bacteria induce comparable cytokine patterns in intestinal epithelial cell-leucocyte cocultures.J Food Prot 2007; 70: 2417-2421
39. Verdú EF, Bercík P, Bergonzelli GE et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 826-837
40. Heading R, Bardhan K, Hollerbach S et al. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24: 207-236
41. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86
42. Kajander K, Krogius-Kurikka L, Rinttila T et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 463-473
43. Shanahan F. Irritable bowel syndrome: Shifting the focus towards the gut microbiota. Gastroenterology 2007; 133: 340-342